Articles tagged with Lung Cancer
A Phase I/II trial tests the safety and efficacy of PR610 in patients with advanced cancer. The study aims to deliver a targeted approach, activating the compound in tissues with low oxygen levels characteristic of many cancers.
A recent University of Colorado Cancer Center case study found a patient with ALK+ lung cancer who tested negative for the EML4-ALK fusion gene using the FDA-approved FISH assay, yet showed dramatic response to crizotinib. Next-gen sequencing revealed genetic shards that may have avoided detection by the test.
Recent studies suggest that colonoscopy-related factors are more predictive of colorectal cancer risk than polyp characteristics. High levels of lead exposure also pose significant health risks, even at low blood lead levels. Meanwhile, a new lung cancer screening model shows high accuracy in identifying patients who will benefit from ...
A lung cancer risk prediction model developed at the University of Liverpool has been shown to be a viable tool for selecting high-risk individuals. The model was tested in international datasets and found to be more effective than smoking duration or family history alone in predicting individuals at risk.
Researchers have identified an experimental drug, GSIs, that blocks Notch and prevents lung cancer growth in mice without treatment-related side effects. This discovery brings new clues for the treatment of lung cancer and is being tested in co-clinical trials.
Researchers have identified how EPHA3 gene mutations may promote lung cancer. The study found that loss of the gene diminishes its tumor-suppressive effect, potentially sparking tumor growth. The findings suggest that therapies targeting a downstream pathway may be beneficial for tumors with mutant EPHA3.
Scientists investigate the use of novel AKT inhibitor MK-2206 in combination with erlotinib as a second-line defense for patients with non-small cell lung cancer (NSCLC) who have developed resistance to erlotinib. A Phase II trial has shown promising initial results.
Researchers from the British Columbia Cancer Research Center analyzed lung tumors exposed to arsenic, highlighting genetic and epigenetic changes driving carcinogenesis. These findings may help prevent arsenic-related cancer in regions with low exposure levels.
Researchers are developing a multiple marker test in peripheral blood to detect lung cancer, promising an earlier diagnosis. The test discriminated between healthy donors and patients with non-small cell lung cancer (NSCLC) with high accuracy.
Chronic obstructive pulmonary disease (COPD) increases lung cancer risk through a novel mechanism involving long-term oxygen depletion and HIF-2a tumor growth signaling. COPD-induced signals may be susceptible to prevention or treatment with VEGFR-2 and EGFR inhibitors.
A new rehabilitation program developed by Michigan State University's Amy Hoffman uses the Nintendo Wii-Fit Plus to promote light-intensity walking and balance exercises. The program has shown excellent improvement in reducing cancer-related fatigue levels over time.
Researchers at Kaiser Permanente Southern California identified 7,112 patients with lung nodules using existing medical records. They developed an automated method that classifies nodules with 96% sensitivity and 86% specificity compared to clinician review.
Researchers at Mayo Clinic found that early-stage lung cancer cells use a biological process called epithelial-mesenchymal transition (EMT) to bypass growth controls and enable uncontrolled growth. This discovery offers new clues for a potential approach to treating lung and possibly other cancers as early as possible.
Researchers identify microRNA-320a as a key regulator of glycolysis in tumors and unused muscles, potentially leading to new treatments for lung cancer and improving ventilator recovery. This discovery offers a significant therapeutic leap for numerous diseases and health conditions.
Researchers at UCSF have discovered that a human protein called AXL drives resistance to Tarceva, which suggests that blocking the protein may prevent resistance to the cancer drug. This discovery may lead to better treatments involving precision medicines that combine Tarceva with new drugs designed to block AXL.
Researchers discovered that combining EGFR inhibitors with Wnt pathway inhibition can improve the durability of lung cancer remission. The Wnt pathway allows lung cancer cells to escape from EGFR-targeted therapy, but disrupting this pathway could lengthen the usefulness of existing treatments.
A new study reveals dramatic differences in lung cancer death rates among women born between 1930s and 1970s in various US states. California shows a decline in lung cancer death rates, while many southern states experience an increase, highlighting the need for stronger tobacco control policies.
Researchers are enrolling patients to detect lung cancer through volatile organic compounds in exhaled breath. Early detection can significantly improve treatment options and survival rates.
The American Association for Thoracic Surgery task force recommends expanded lung cancer screening guidelines using low-dose computed tomography (LDCT) for high-risk individuals. The new guidelines increase the recommended age range to 79 and expand eligibility to smokers and former smokers with specific risk factors.
Researchers discovered a new mechanism that promotes lung cancer growth and survival by regulating autophagy, a complex process initiated under stressful conditions. The protein BI-1 was found to protect lung cancer cells and suppress tumor growth by modulating intracellular signals.
Researchers found that perioperative chemotherapy improved overall survival in patients with limited large cell neuroendocrine tumors or small-cell lung cancer after surgery. The study of 74 patients showed a significant difference in overall survival between those who received chemotherapy and those who did not.
A study published in the Journal of Thoracic Oncology found that stereotactic ablative radiotherapy is an effective treatment option for elderly patients with stage I non-small cell lung cancer. The treatment did not negatively impact health-related quality of life, and functional and symptom outcomes remained stable after two years.
A study published by the International Association for the Study of Lung Cancer found that high-volume hospitals and thoracic surgeons have lower mortality rates compared to general surgeons. The researchers recommend a national audit program to evaluate institutions based on quality parameters, including hospital volume.
Researchers at UNC Health Care identify a key genetic switch that determines melanoma's ability to spread. Inactivating the LKB1 gene causes non-aggressive cells to become highly metastatic.
Researchers discovered that ADAM28 inhibits VWF-mediated apoptosis in cancer cells, leading to increased lung metastases. Inhibition of ADAM28 expression or activity significantly reduced lung metastases and increased cancer cell apoptosis.
LDK378 shows encouraging activity in patients with ALK+ non-small cell lung cancer, including those who no longer respond to crizotinib. The compound is well-tolerated and its optimal dose is being further tested.
A novel compound has shown significant benefits in patients with KRAS-mutant non-small cell lung cancer, improving treatment response and survival times. The study's findings suggest a potential effective treatment for this common subtype of lung cancer.
A new study found that active tuberculosis is an independent predictor of lung cancer death in the elderly. The research analyzed data from 61,239 subjects aged 65 years or older and found a significant association between tuberculosis and lung cancer mortality.
Researchers created a new anti-cancer drug named BP-1-102 that targets the Stat3 protein, which triggers cancer development in various types. The drug remains effective even when administered orally, unlike most current treatments requiring intravenous injection.
A systematic review found that low-dose computerized tomography (LDCT) screening can reduce lung cancer mortality rates among high-risk individuals. The study analyzed 8 randomized controlled trials and 13 cohort studies, with the National Lung Screening Trial demonstrating a significant benefit. However, potential harms of LDCT screen...
A recent study suggests a positive correlation between tumor size and chemotherapy efficacy in surgically resected patients with node-negative non-small cell lung cancer. The study found no clear threshold for tumor size that correlated with a benefit from chemotherapy.
Researchers found that tenasin-C gene expression and nodule size can predict lung cancer with improved accuracy. The study used bronchoscopic microsampling to collect fluid from lung nodules, showing promise for a less invasive diagnostic technique.
A recent study found VATS resection in CT-screened high-risk Danish population yielded higher incidence of early stage lung cancer. The study detected 68 lung cancers in the screened group versus 24 in the unscreened group, with 51 patients suitable for surgery and 84% undergoing VATS.
A UNC-led team discovers that lung cancer molecular subtypes correlate with distinct genetic alterations and patient response to therapy. The study refines their previous report on three molecular subtypes of non-small cell lung cancer, suggesting new avenues for targeted treatment.
Researchers combine a blood test with CT imaging to screen for cancer, aiming to detect early-stage lung cancers while reducing biopsies and operations. The trial may improve survival rates and reduce the toll of lung cancer on patients.
A study of over 20,000 older patients with non-small-cell lung cancer found that younger patients were more likely to receive treatment than their older counterparts. The research suggests that age alone is not a reliable indicator for cancer treatment decisions, and other health factors should be considered.
A study published in JNCI found a strong association between genetic variants rs1051730-rs16969968 and objective measures of tobacco exposure, indicating that lung cancer risk is largely mediated by level of tobacco exposure. The research used data from six independent studies to analyze self-reported cigarette consumption and plasma o...
Researchers at Mayo Clinic have identified a single gene, MMP-10, that promotes the development and spread of lung cancer. This discovery suggests that targeting this gene may be an effective way to treat non-small cell lung cancer.
A new analysis found that Hispanic lung cancer patients have a 15% lower risk of dying compared to white patients, with black patients slightly more likely to die. The study also identified higher frequencies of less serious lung cancer types in Hispanics, which may be linked to genetic or environmental factors.
Researchers have identified potential biomarkers for personalized medicine in lung cancer, such as a test that predicts patient response to certain treatments. The findings suggest that these innovative approaches could lead to more effective treatment strategies for patients with lung cancer.
A 50-gene predictor has been found to accurately identify patients with low risk of relapse after surgery. The gene signature is related to the activity of B lymphocytes and suggests an enhanced immune response against the tumor.
Researchers present new methods for early lung cancer detection, including digital chest tomography and a blood test for BARD1 antibodies. These techniques have shown promising results in detecting lung cancer with high sensitivity and specificity.
A new analysis of the TORCH trial found that erlotinib is most effective in patients with EGFR mutations, while those with wild-type tumors should receive standard chemotherapy first. The study confirms the importance of biomarker testing to guide treatment decisions.
Researchers analyzed data from 4,168 Medicare beneficiaries with advanced non-small cell lung cancer aged 65 or older. They found no significant difference in overall survival between those treated with bevacizumab and those receiving standard chemotherapy alone. The study's findings suggest that bevacizumab should not be considered th...
A study by Dana-Farber Cancer Institute researchers found that adding bevacizumab to standard chemotherapy for non-small cell lung cancer in patients over 65 did not significantly increase survival rates. The treatment approach was previously approved by the FDA but failed to show substantial benefits.
Researchers found that fine needle aspiration is highly sensitive for diagnosing lung cancer, but has a high rate of false negatives, especially in larger lesions. The study recommends repeat imaging to monitor for growth and suggests this method can help patients avoid unnecessary surgery.
A recent study published in the Journal of Thoracic Oncology reveals that Japanese patients with lung cancer are more likely to harbor specific genetic mutations and have a different risk profile compared to Western patients. The research highlights the importance of considering genetic factors in lung cancer diagnosis and treatment.
Researchers analyzed four studies and found that regular follow-up reduces crisis-driven health episodes. While no preferred method was determined, the authors recommend guidelines for initial specialist appointments and protocol-driven follow-up led by a lung cancer clinical nurse specialist.
Three noteworthy studies were presented, including a study on KRAS in non-small cell lung cancer patients and another on dacomitinib's favorable clinical benefits. Additionally, researchers validated the role of tumor lymphocytic infiltration as a favorable prognostic factor for resectable non-small cell lung cancer.
A new study by Rush University Medical Center found that lung cancer screening with low-dose spiral CT scans can detect early-stage disease and reduce cancer-related deaths. The study estimates that commercial insurers should consider providing this benefit to high-risk individuals, which could lead to significant cost savings.
A phase II clinical trial showed encouraging survival in patients with stage 3B/4 non-small cell lung cancer (NSCLC) treated with belagenpumatucel-L. The median survival rate was 14.5 months, and the five-year survival rate was 20%. Patients with stable disease had a longer median survival of 44 months.
A University of Colorado Cancer Center study found that men taking crizotinib for lung cancer experience a significant drop in testosterone levels, which can lead to fatigue, low bone density, and decreased sex drive. Regular monitoring and treatment of testosterone deficiency can improve patients' overall quality of life.
Scientists at Fox Chase Cancer Center discovered a link between estrogen and tobacco smoke, suggesting that new therapies targeting estrogen metabolism may help prevent or treat lung cancer. Estrogen metabolites increase in the lungs of mice exposed to tobacco smoke, promoting cell growth and damage.
Researchers at Moffitt Cancer Center found that 38% of lung cancer patients suffer from depression, with greater stigma levels related to higher depressive symptoms. Psychotherapeutic approaches may help alleviate or prevent depression by altering perceptions of stigma.
Researchers found that adding RNAi to standard TKI or antibody therapy can enhance the effect of therapy on NSCLC cell death and slow cell growth. The treatment may benefit patients with EGFR mutations who do not respond to TKI, or those whose cancer is driven by overactive EGFR production.
A recent study published in the Journal of Thoracic Oncology suggests that pleurectomy/decortication (P/D) is a superior approach to extrapleural pnemonectomy (EPP) for patients with early-stage malignant pleural mesothelioma. P/D resulted in significantly better survival rates and lower mortality and morbidity compared to EPP.
Research reveals that BRG1 gene mutations render tumor cells unresponsive to hormones like retinoic acid and steroids, leading to continued growth and spreading.
A panel of 10 serum protein biomarkers shows promise in predicting lung cancer risk and aiding early detection. Research suggests that these biomarkers could reduce the number of unnecessary lung biopsies needed, offering a more targeted approach to diagnosis.
A recent study published in Journal of Thoracic Oncology suggests that CYFRA21-1 levels can reliably indicate patient response to chemotherapy for non-small cell lung cancer (NSCLC). Higher baseline concentrations were linked to poorer overall and failure-free survival. Further research is needed to confirm these findings.
Between 1975-2000, US lung cancer mortality declined significantly due to reduced smoking rates. Tobacco control measures such as increased taxes and smoke-free laws contributed to this decrease.